Poly Medicure Limited
Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110 020 (INDIA)
T: +91-11-33550700, 47317000
E: info@polymedicure.com W: polymedicure.com
CIN: L 40300DL1995PLC066923

POLYMED

Date: 07th August, 2026

Scrip Code: - 531768

The Manager,
BSE Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

Scrip Code:- POLYMED

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Sub: Submission of Investor's Presentation

Dear Sir/Madam,

Pursuant to Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor's Presentation with respect to Unaudited Financial Results (Standalone & Consolidated) for First Quarter ended on June 30, 2026.

The same is also available on the website of company i.e. www.polymedicure.com .

Request you to take the same on records.

Thanking You,
Yours Sincerely

For Poly Medicure Limited

AVINASH CHANDRA
Digitally signed by AVINASH CHANDRA
Date: 2026.08.07 16:44:40 +05'30'

POLY MEDICURE LIMITED New Delhi

Avinash Chandra
Company Secretary
M. No. A32270

s

Investor Presentation : Financial Results - Q1 FY27

August 7, 2027

POLYMED

Disclaimer

This presentation has been prepared by Poly Medicure Limited (the "Company"), content of which was compiled from sources believed to be reliable for informational purposes only and are based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. Subsequent developments may impact the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm. Contents in the Presentation do not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction. Prospective and existing investors should make their own evaluation of the Company as the information provided here does not purport to be all inclusive or to contain all of the information a prospective or existing investor may desire. Interested parties shall conduct their own due diligence and investigation on the information, before relying and acting thereon. Company makes no representation or warranty as to the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding information contained in, or for any omissions from, this information or any other written or oral communications transmitted to the recipient in the course of its evaluation of the Company. This presentation may contain certain "forward looking statements", which are based on certain assumptions and expectations of future events. Actual future performance, outcomes and results may differ materially from those expressed in forward looking statements as a result of a number of risks, uncertainties and assumptions. Though such forward looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward-looking statements or to adapt them to future events or developments.

Company Overview

Polymed at a Glance

2nd Largest Medical Devices Player in India | Largest Exporter of Medical Consumables

Figs in Rs. Crs unless specified

PRODUCT PORTFOLIO



15 Manufacturing Plants Across 5 countries

225+ Medical Devices

125+ Countries

390+ Patents Granted

1000+ Distributors across India & Globally

GEOGRAPHIC MIX



Rising Contributions from **Domestic** and **European Markets**

Polymed Flywheel

Integrated business model serving customers globally



Clinical Engagement
- **60+** clinical experts;
- **4,000+** annual customer engagement programs globally

In-House Product R&D
- **390+** patents
- **30+** new products launches annually
- **90+** R&D professionals

Distribution Network
- **1000+** distributors globally;
- Supplying across **125+** countries

Manufacturing, Packaging and Sterilization
- **15** plants in **5** countries
- **Significant investment** in backward integration, Automation and sterilization

Sales & Marketing
- **590+** direct-sales reps in India, US, Italy, and Mexico;
- **Expanding presence** in other key markets

Strong Quality and Regulatory Capability
- **200+** Quality & Regulatory professionals
- Product registration in **100+** countries

Diversified Segment and Geographic Mix

Rising contribution from New Segments | Deepening Presence in the Indian Market

Segmental Revenue Mix

Figs in Rs. Crs unless specified

Particulars	FY20	FY 22	FY 24	FY26	CAGR (20-26)
Infusion Therapy	466	555	925	997	**14%**
Renal	26	60	94	187	**39%**
Others	196	308	356	691	**23%**
Total Operating Revenue	**687**	**923**	**1,376**	**1,875**	**18%**

PORTFOLIO MIX



Geographical Revenue Mix

Figs in Rs. Crs unless specified

Particulars	FY20	FY 22	FY 24	FY26	CAGR (20-26)
India	187	303	418	582	**21%**
Europe	202	294	454	597	**20%**
RoW	299	325	504	696	**15%**
Total Operating Revenue	**687**	**923**	**1,376**	**1,875**	**18%**

basis consolidated financial statements

Moving up the value Chain

From essential consumables to advanced Medical Technologies

1997
INFUSION THERAPY

Global Leadership
3rd largest IV cannula manufacturer globally

2018
RENAL CARE

First Indian Company to indigenously manufacture **dialysis products**

2019
CRITICAL CARE

Focused on products used in **ICU, Neonatology and Oncology**

2024
CARDIOLOGY

- Entered **cardiology** in **2024**
- Launched **DES** in India in **2025**
- Initiated a **2000 patient clinical** trial in India and Europe in 2025

2025
ORTHOPAEDICS

- Acquired **Citieffe**
- Overtime to create a comprehensive portfolio

EXPANDING TAM CREATING LONG-TERM VALUE

1997	2000	2018	2019	2024	2025
Infusion Therapy & Vascular access	Transfusion	Renal Care	Critical Care	Cardiology	Orthopaedics

STRONGER PORTFOLIO GREATER IMPACT

A 30 years compounding story – Growth Engine Just warming up

Proven yesterday. Scaling today. Defining tomorrow.

POLYMED 1.0

Foundation

FY 1996–2020

- **IPO 1996** (Rs 55 Lakhs)
- Compounding quietly on **internal accruals**;
- Built **global leadership** in **Infusion Therapy**

POLYMED 2.0

Inflection

FY 2020–2026

- **First Institutional Raise** (Rs 1,400 cr)
- Multifold **capacity expansion**;
- Incubated new **segments** such as **Cardiology, Critical Care,** and **Orthopedics**

POLYMED 3.0

Ascent

FY 2027 onwards

- Unlocking value via **organic & inorganic expansion**;
- **Leverage tech** for scaling high complexity verticals globally;
- Deepen **direct customer** access
- Strong Balance Sheet & Liquidity (Rs ~850 cr cash)

	2000	2010	2020	2026
Revenue	10	137	687	1,875
EBITDA	2	29	166	458

Figs in Rs. Crs unless specified

Polymed 1.0 (1996 to 2020): Foundation

Resiliently built a global medical device platform with equity infusion of INR 5.5mn

~25 years | Dedicated Focus | Bootstrapped

From **INR 5.5 Mn IPO** in 1996 built a globally competent infusion therapy platform

Growth Funded by Internal Accruals

Manufacturing Footprint

- **8** Plants
- **4** Countries

Production Capacity

- **~1.0 Bn** Units Annually
- **+63,000 sq m.** Total Plant Area

Revenue (FY20) ~INR 7.0 Bn

- **~68%** Infusion Therapy
- **~73%** International Business

Profitability (FY20)

- **~INR 1.7 Bn** Op. EBITDA
- **~24.1%** EBITDA Margin

3rd Largest IV cannula manufacturer globally

1st Indian company to indigenously manufacture dialysis products

Key Products


IV Cannula


IV Sets


Endotracheal Tubes


Urine Collection Bag


Transfer Bag


Single Blood Bag


Extension Lines


Disinfecting Cap

Key Events

- **2003** JV in **Assuit, Egypt**
- **2009** Manufacturing **Plant in China**
- **2016** **R&D Center**
- **2018** **Plan1Health Acquisition**

Polymed 2.0 (2021 to 2026): Inflection

The inflection: capital, capacity, categories, countries — all scaling in parallel

INR 14 Bn Institutional Equity Raised | Portfolio Expansion

Growth Capital utilized towards capacity expansion, **deeper penetration** in **Renal & Critical Care**, alongside venturing into **Cardiology & Orthopedics**

From Capital to Compounding

Manufacturing Footprint

15	5
Plants	Countries

Production Capacity

~1.9 Bn	+95,000 sq m.
Units Annually	Total Plant Area

Revenue (FY26) ~INR 18.7 Bn

~53%	~69%
Infusion Therapy	International Business

Profitability (FY26)

~INR 4.6 Bn	~24.4%
Op. EBITDA	EBITDA Margin

PTCA Balloon

Central Venous Catheters



DES

PICC Ports

New Products

Arterial Catheter

DEB



Guiding Catheter

Dialysis Machine

Key Events

- **2021** QIP : INR 4 Bn
- **2024** QIP : INR 10 Bn
- **2025** **PendraCare & Citieffe** Acquisition | Initiated **3 New Plant** construction | **2,000** patient trial of **DES**
- **2026** **Medyneo (Brazil)** Acquisition | **Haridwar Plant** operationalization

Polymed 3.0 (2027 onwards): Inflection

The next chapter isn't incremental - it's exponential !

Vision 2030 2.0x Revenue | Industry-leading margins | Globalization of the Business Model

Climb the Tech Ladder

- **Double R&D spend**
- **Globalize high-complexity verticals** — cardiology & critical care
- Greater focus on clinical led engagement with end-stakeholders

Deepen Market Presence

- **30+ new products under** registration in Europe
- **Deepen clinical engagement** with customers & stakeholders
- **Import-substitution** success into newer India segments
- 100+ new sales associates annually

USA Market Expansion

- **15 approvals** obtained, 11–13 more in the pipeline
- **GPO contracts** signed across multiple accounts
- **Launch new hi-tech launches**

Business Expansion

- **2 upcoming plants**
- **Infrastructure** set for the next 3–5 years of growth
- **25–30 new products** launches

M&A Integration

- **Replicate the P1H playbook** for PendraCare & Citieffe
- **Leveraging product and customer strengths**
- **Collaborate R&D** & compounding production capabilities

Go- Direct Strategy

- **Organic & inorganic** expansion — Brazil, SEA, Europe
- **Leverage** existing customer relationships
- **New products registration**

Plan1Health

Since 1995 | Italy | Acquired 100.0% in 2019 | EV ~Euro 4.2 Mn

1 WHAT WE ACQUIRED?

- **Integrated** developer & seller of **long-term infusion** devices, **oncology** products and an innovative **pain-control** device;
- Specialist in long-term **implantables**
- **A "made in Europe" critical care** brand in oncology segment

2 WHY WE ACQUIRED?

- **Entry into Critical Care** segment
- Access to **clinical data and technology**
- **Regulatory & technical advantage** in developed markets:
  - ✓ **EN ISO 13485:2003** certified;
  - ✓ Products compliant with **EU MDR & CE**;
  - ✓ **ISO Class 7** Clean Room
  - ✓ Many devices classified as **Class III Medical Devices**
- **Competent position**
  - **Sole approved supplier** for one of the largest OEM for Class III implants;
  - **Global distributor network**

3 SYNERGIES REALISED

3.2x	11.8x	+970 BPS
REVENUE	EBITDA	MARGIN



How we acted? - 5 repeatable plays

- ✓ Accelerated product launches
- ✓ Leveraged India manufacturing to reduce cost
- ✓ Invested in enhancing direct sales capabilities
- ✓ Widened distribution reach
- ✓ Collaborated on R&D and marketing

PendraCare Group – Unique Cardiology Catheter Platform

Since 2011 | Netherlands | Acquired 90.0% in 2025 | EV : Euro 18.8 Mn

50+ Countries	**50+** Distributors	**1,150 m^2** Cleanroom	**3,800 m^2** 3 Leased Facilities	**1.5M+** Capacity/year	**65+** Employees

A **Unique & One of the few independent big** players in **Interventional Cardiology Catheter** business.

- Long term relationships with **leading global OEMs;**
- **Patented** product portfolio
- **Financial Overview** (CY2025):
  - -Revenue: ~Euro 8,200 K;
  - -Gross Margin: ~Euro 5,591 K;
  - -EBITDA: ~Euro 84 K



ACQUISITION RATIONALE

- **Strategic fitment** to grow **Cardiology** biz globally
- Product registration in **60+ countries including Europe and US**
- **ISO 13485 & FDA Approved** manufacturing
- Strong **distribution network** & **relationship with 2 large OEMs**

GROWTH DRIVERS

- ✓ Expanding distribution network
- ✓ New lease signed for **consolidating operations (~2,300m^2);** transition expected in CY 2028
- ✓ Identifying new CDMO projects

SYNERGIES EXPECTED

- ✓ Transferring parts of production process to India;
- ✓ Collaborating on R&D;
- ✓ Leveraging distribution network
- ✓ Deepening global penetration in Cardiology

Citieffe - Fully integrated supplier of high-quality Trauma Implants

Since 1962 | Italy | Acquired 100.0% in 2025 | EV ~Euro 31.0 Mn

30+ Countries	**25+** Distributors	**45+** Patents	**2,100 m^2** 2 manufacturing facilities	**85.0%+** Sales from countries with direct presence	**90+** Employees R&D (5+) & KOL (50+)

A **fully Integrated** developer, manufacturer, and distributor in **Trauma and Extremity** space.

- **Rank 2 (In Italy & Mexico)** with ~12.0%+ market share.
- **Key Products**: Internal/External Fixators, Instruments, Navigation Systems, etc.
- Low customer **complaint rate of <0.001%**
- **Financial Overview** (CY2025):
  - -Revenue: ~Euro 17,701 K;
  - -Gross Margin: ~Euro 12,093 K;
  - -EBITDA: ~Euro 3,150 K



ACQUISITION RATIONALE

- Access to **fastest growing Trauma & Extremity** (with-in the large Orthopedics) market
- **MDR clearance**; **products registered** with FDA US, LATAM, and **25+ countries**
- **ISO 9001, ISO 13485 & FDA certified** manufacturing
- **Unique navigation software** for nailing systems

GROWTH DRIVERS

✓ Strategic **expansion in US**, largest orthopedics market with **prices 4-5x of Europe;**

✓ Plan to **add Plates** to the product portfolio, **doubling the TAM;**

✓ Maximize value from **existing product families**

✓ Unlock full **market penetration potential**

SYNERGIES EXPECTED

✓ Deeper penetration in US and Europe;

✓ Product portfolio expansion

✓ Collaboration on R&D;

✓ Manufacturing & Procurement cost saving

Robust Financial Performance Delivering Strong TSR

POLYMED

Margin%

Revenue from operations (INR Cr)



Gross Profit (INR Cr)



Operating EBITDA (INR Cr)



PAT (INR Cr)



Net Worth (INR Cr)



~INR 855 Crs. in Cash & Cash Equivalents – Reserve allocated for strategic initiatives

basis consolidated financial statements

Strong Promoters and Experienced Leadership Team

Promoters

Mr. Himanshu Baid
(Managing Director)
Co-founder of Poly Medicure, Mr. Baid has over 30 years of experience in the medical device industry and has been instrumental in the company's growth and innovation. He was honored with the EY Entrepreneur of the Year Award, 2024 in the Life Sciences and Healthcare sector.

Mr. Rishi Baid
(Joint Managing Director)
Co-founder of Poly Medicure, Mr. Baid oversees operations and strategic initiatives, contributing significantly to the company's expansion and product development with an experience of 28 years.

Mr. Vishal Baid
(Executive Director)
Mr. Vishal Baid is responsible for overall Marketing and in charge of Manufacturing activities in Jaipur with an experience of 25 Years.

Mr. Jugal Kishore Baid
(Non-Executive Director)
A founding member, Mr. Baid has played a pivotal role in establishing the company's foundation and continues to provide strategic guidance with an experience of 56 years.

Experienced Leadership Team

Mr. Alessandro Balboni
(Non-Executive Non-Independent Director)
Mr. Balboni brings international business experience, particularly in the European healthcare market, enhancing the company's global perspective with an experience of 23 years.

Mr. Pankaj Kumar Gupta
(Executive Director)
Mr. Pankaj Kumar Gupta is an accomplished and result-driven Operations Leader with over 35 years of experience.

Mr. Indranil Mukherjee
(CEO – Asia Pacific & India Business)
Mr. Indranil Mukherjee brings 30+ years of medical technology experience across critical care, infusion, renal care, and vascular technologies. Former CEO, Translumina; MD, B. Braun India.

Mr. Rahul Gautam
(President – Strategy & Corporate Development)
Mr. Rahul Gautam has 20+ years of experience in Corporate Strategy, M&A and Capital Markets. He has led M&A and fundraising deals exceeding US$8 billion.

Mr. Naresh Vijayvergiya
(Chief Financial Officer)
Mr. Naresh Vijayvergiya is an accomplished finance executive with 22+ years of experience culminating in CFO and President-level roles, driving financial strategy in manufacturing and commodities sector.

Mr. Sujit Gupta
(Senior Vice President & Head International Business)
Mr. Sujit Gupta has 26+ years of international sales experience, driving Poly Medicure's global expansion through strategic partnerships, distribution networks, and export growth.

Mr. Pascal Govi
(CEO – Citieffe Group)
Mr. Pascal Govi is a global medtech leader with 30+ years of experience, CEO of Citieffe since 2019 driving international growth.

Mr. Sander Hartman
(CEO – Pendracare)
Mr. Sander Hartman is a seasoned medical device executive with 20+ years of global experience, currently serving as CEO of PendraCare International. Associated with Pendracare group since 2012.

Mr. Heyward Powe
(Vice President, Sales & Business Development – North America)
A senior medical device executive with over 27 years of experience in Vascular Access, Oncology, Cardiology, and Surgery.

Robust Governance Framework

Non-Executive Board

Mr. Devendra Raj Mehta
(Chairman, Non-Executive Non-Independent Director)
A seasoned IAS officer and former Chairman of SEBI, Mr. Mehta brings extensive regulatory and governance experience to the board with an experience of 54 years.

Mr. Vishal Gupta
(Non-Executive Independent Director)
Mr. Vishal Gupta is the Managing Director of Ashiana Housing Ltd., known for pioneering senior living and middle-income housing in India with an experience of 25 years.

Mr. Vimal Bhandari
(Non-Executive Independent Director)
An experienced finance professional, Mr. Bhandari provides valuable insights into financial planning and risk management with an experience of 35 years across IL&FS, AEGON N.V & IndoStar Capital Finance Limited.

Ms. Sonal Mattoo
(Non-Executive Independent Director)
Ms. Mattoo specializes in human resources and organizational development, supporting the company's talent management strategies with an experience of 28 years.

Dr. Ambrish Mithal
(Non-Executive Independent Director)
A renowned endocrinologist, Dr. Mithal provides medical expertise, aligning the company's products with healthcare needs with an experience of 39 years.

Mr. Amit Khosla
(Non-Executive Independent Director)
With a strong background in law and corporate affairs, Mr. Khosla aids in ensuring compliance and ethical standards with an experience of 24 years.

Awards & Accolades

POLYMED

Himanshu Baid, MD, Poly Medicure, Healthcare Icon/Leader of the Year 2025 by ET Healthcare Awards

Himanshu Baid, MD, Poly Medicure Healthcare Entrepreneur of the Year 2025 by Financial Express

Medical Devices Provider of the Year 2025 by Financial Express

Best CSR Initiative in Healthcare, Education & Social Welfare Award by Medgate Today

Hurun India 2025 List of India's 500 Most Valuable Companies

Leading Brand in Medical Devices by Elets

Bhamashah Award by Govt. of Rajasthan, Education Dept.

Top Exporter of Plastic Medical Disposables from India for 10 Years by Plexconcil

Excellence in Medical Equipment Innovation by India Health Next Awards

Innovative Health Technology Provider of the Year by ET Rajasthan Business Awards

Mr Himanshu Baid, MD, Poly Medicure, EY Entrepreneur of the Year Award 2024 - Lifesciences & Healthcare Category

Hurun India 2024 List of India's 500 Most Valuable Companies

Top 75 Industrial Innovative Company of the Year 2024 by CII

ET Best Healthcare Brands 2024

The Next 500 Companies 2023 by Fortune India

Towards our Commitment to a Sustainable World

- **Approx. 70% facilities** are certified under **ISO 14001:2015**

ENVIORNMENTAL MANAGEMENT SYSTEM

- **Annual Health check-up** of **28 employees**
- Well-being **health assessments** for **2,239 workforce**

EMPLOYEE WELLBEING

- **9.9 MWp Solar Energy Plant**
- **Generated approx. 3,214 MWh unit**
- **Reduced Scope-2 emission approx. 2,281 tCO2***

SIGNED PPA AGREEMENT

SUSTAINABLE DEVELOPMENT

- Reduced Scope 2 emissions **by 8%** compared to **FY 24-25**
- Enabled by greater utilization of **solar power** and renewable energy **PPAs**

SCOPE 2 EMISSION

- **Achieved ~6x growth** in **solar power generation** compared to Q1 FY 24-25

SOLAR GENERATION

- **BRSR Report** Assessment is in progress
- **Sustainability Report** in progress

ASSESMENTS & INSIGHTS

- **LCA of two products – Ongoing**

Life Cycle Assessment & Critical review

***The reported Solar units are tentative, as the Monthly Energy Account (MEA) from DHBVN has not yet been received and the renewable energy (RE) adjustment is pending

Financial Results & Key Updates – Q1 FY 27

Financial Performance Summary Q1 FY27

POLYMED

Figs in Rs. Crs unless specified Acquisition Impact Margin,%

Standalone

Revenue



Gross Profit



Operating EBITDA[1]



Consolidated

Revenue



Gross Profit



Operating EBITDA[1]



No of Patents
399

Cash & Cash Equivalents (INR Crs)
854.7

[1]Excludes Other Income

Key Updates

POLYMED

Key Business Updates

- Appointed **Mr. Indranil Mukherjee as CEO – India & APAC (Ex. B Braun & Translumina)**
- Appointed **Mr. Renato Rocha as CEO** (effective August 2026) of Polymed Brazil **(Ex Descarpack, B.Braun & GE Healthcare)**
- Appointed Abhimanyu Hooda as Head of Renal Business in India **(Ex: Nipro, Fresenius and DaVita)**
- Cumulative **stent deployments surpassed ~13K units (July 2026); DEB-Ex-Vivo preclinical** data is obtained with **encouraging results**
- **PACIFIER**- (DES - Clinical Registry of 2000 patients) **840+ Patients** enrolled, **with full enrollment targeted by end FY27**
- Grew cumulative **dialysis machine installations to ~1,100 units**, reinforcing our market presence

Financial Highlights

- Consolidated **Q1 FY27** revenue growth **30.3% Y-o-Y;** Q1 FY27 **Domestic** revenue growth **16.2% Y-o-Y** and **International** revenue grew by **36.7% Y-o-Y;**
- Average price increase of **~4-5%** across the business in Q1 FY 27 vs Q4 FY 26
- **Q1 FY27 Standalone Operating EBITDA** at **28.0%, well above the 25%-27% guidance range;** Q1 FY27 **Consolidated Operating EBITDA margin** at **24.1% within the guidance of 23-25%**
- Adequate liquidity of **Rs 854.7 Crs** as at 30th June, 2026

Product Launches & R&D

- **6 new products launched in Q1 FY27 across Infusion Therapy and Critical Care**
- **R&D team strength of 90+ across** India, Italy and Netherlands

ESG

- Achieved **~18% reduction in scope 2 emissions** compared through increase utilization of solar and renewable energy PPA
- Achieved **6x** growth in the solar power generation

Awards

- Recently received "**Custodian Award for Best CSR Initiative in Healthcare, Education and Social Welfare**" by Medgate Today
- Poly Medicure awarded **"500 Most Valuable Companies List 2025 "** by Hurun India

Financial Performance Analysis

Standalone Financial Performance Summary

Figs in Rs. Cr. unless specified

Particulars	Q1 FY 27	Q1 FY 26	YoY Growth %
Revenue from Operations	**431.1**	**384.0**	**12.3%**
-Domestic	*146.0*	*125.7*	*16.2%*
-International	*281.8*	*256.0*	*10.1%*
-Other Operating revenue	*3.3*	*2.4*	*34.6%*
Cost of Good Sold	122.8	122.1	0.6%
Gross Profit	**308.3**	**262.0**	**17.7%**
Gross Profit %	*71.5%*	*68.2%*	***330 bps***
Employee Benefit Expenses	88.9	69.2	28.5%
R&D Expenses	7.9	7.3	8.5%
Other Expenses	90.7	83.8	8.2%
Total Expenses	**187.5**	**160.3**	**17.0%**
Operating EBITDA	**120.8**	**101.7**	**18.8%**
EBITDA %	*28.0%*	*26.5%*	***154 bps***
Other Income	28.6	41.1	(30.3%)
Depreciation	26.5	23.0	15.3%
Finance Cost	4.4	2.8	55.8%
PBT	**118.6**	**117.1**	1.3%
Tax	30.5	29.1	4.7%
PAT	**88.1**	**87.9**	**0.2%**
PAT %	*19.2%*	*20.7%*	***(151 bps)***
EPS – Basis (Rs)	8.7	8.7	(0.1%)
EPS – Diluted (Rs)	8.7	8.7	(0.1%)

Re- classification has been done wherever necessary

Consolidated Financial Performance Summary

Figs in Rs. Cr. unless specified

Particulars	Q1 FY 27	Q1 FY 26	YoY Growth %
Revenue from Operations	525.4	403.2	30.3%
Cost of Good Sold	139.7	127.2	9.8%
Gross Profit	**385.6**	**276.0**	39.7%
Gross Profit %	*73.4%*	*68.4%*	***495 bps***
Employee Benefit Expenses	126.9	74.4	70.6%
R&D Expenses	7.9	7.3	8.3%
Other Expenses	125.7	88.0	42.8%
Total Expenses	**260.5**	**169.7**	53.5%
Share of profit of an associate	1.6	1.3	17.3%
Operating EBITDA	**126.7**	**107.6**	17.7%
EBITDA %	*24.1%*	*26.7%*	***(257 bps)***
Other Income	33.4	41.7	(19.9%)
Depreciation	36.3	23.4	55.1%
Finance Cost	6.5	3.0	120.4%
PBT	**117.3**	**122.9**	(4.6%)
Tax	32.0	29.9	7.3%
PAT	**85.3**	**93.1**	(8.4%)
PAT %	*15.3%*	*20.9%*	***(566 bps)***
EPS – Basis (Rs)	8.5	9.2	(7.6%)
EPS – Diluted (Rs)	8.5	9.2	(7.6%)

Re- classification has been done wherever necessary

Consolidated Sales Performance Analysis

Figs in Rs. Cr. unless specified

	Consolidated			Organic	
Particulars	**Q1 FY 27**	**Q1 FY 26**	**YoY Growth %**	**Q1 FY27**	**YoY Growth %**
Domestic	146.0	125.7	16.2%	146.0	16.2%
International	376.1	275.1	36.7%	303.8	10.4%
Other Operating Revenue	3.3	2.4	34.6%	3.3	34.6%
Total Operating Revenue	**525.4**	**403.2**	**30.3%**	**453.1**	**12.4%**
Geographical Revenue Mix					
India	146.0	125.7	16.2%	146.0	16.2%
Europe	187.3	130.3	43.8%	153.1	17.6%
RoW	188.8	144.8	30.3%	150.7	4.0%
Other Operating Revenue	3.3	2.4	34.6%	3.3	34.6%
Total Operating Revenue	**525.4**	**403.2**	**30.3%**	**453.1**	**12.4%**

RoW growth (ex-acquisition) was impacted by crisis in Middle East which de-grew by ~32% on a Y-o-Y basis

Revenue Mix- Domestic & International



Geographical Segment



Segment Wise Sales Performance Analysis

Figs in Rs. Crs unless specified

	Q1 FY27	Q1 FY26	YoY Growth %
Infusion Therapy	259.2	233.3	11.1%
Orthopaedics	49.2	-	-
Renal	43.2	44.9	(3.8%)
Cardiology	28.6	2.9	897.0%
Others	141.9	119.7	18.5%
Export Incentive	3.3	2.4	34.6%
Total Operating Revenue	**525.4**	**403.2**	**30.3%**

Revenue Mix- Domestic & International*



Infusion Therapy

- Delivered strong growth in the domestic market led by increasing share of higher value added products and price hikes
- Witnessed recovery in international markets despite degrowth in in the Middle Eastern markets by 32% on account of West Asia crisis

Orthopaedics

- Reflects the consolidation of revenue of Citieffe

Renal Business

- Renal Business in the domestic market was impacted due to continued pricing pressure from Chinese players; Polymed decided to increase prices to cushion for the impact of RM price increase
- Basis an application by Polymed, Govt has initiated an anti-dumping investigation on imports of Dialyzers from China PR and Malaysia

Cardiology

- The growth was led by the impact of acquisition of Pendracare and scale up of the domestic business

- Revenue mix continues to diversify with Infusion therapy now accounting for 50% of the consolidated revenue

*Excluding Export Incentive

Shareholding Pattern as on 30th June 2026



Top 10 Institutional Shareholders		
Sr. No	Name	% Shareholding
1	Quant Mutual Fund	4.6%
2	Lighthouse	2.3%
3	Axis Max Life Insurance	2.1%
4	UTI Asset Management	2.0%
5	WhiteOak Capital	1.5%
6	Vanguard	1.4%
7	Carnelian Asset Advisors	1.3%
8	SBI Mutual Fund	1.2%
10	HSBC Mutual Fund	0.8%
9	Kotak Mahindra Life Insurance	0.7%

Thank You

For any investor related queries reach us at:

Apoorv.Rastogi@polymedicure.com